ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Gall, C
Right arrow Articles by Humbert, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Gall, C
Right arrow Articles by Humbert, M
Eur Respir J 2000; 15: 978-981
Copyright © ERS Journals Ltd 2000

Case Studies

Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases

C Le Gall, S Pham, S Vignes, G Garcia, H Nunes, D Fichet, G Simonneau, P Duroux, and M Humbert

Churg-Strauss syndrome is an eosinophil-associated, small vessel granulomatous vasculitis, characterized by late onset asthma, upper airways disease, eosinophilia, and clinical manifestations of systemic vasculitis. Several cases of Churg-Strauss syndrome have been recognized in patients treated with cysteinyl leukotriene-receptor antagonists and weaned off systemic corticosteroids. These cases have led to a general warning on the possible development of Churg-Strauss syndrome after taking cysteinyl leukotriene-receptor antagonists. The authors report five cases of Churg-Strauss syndrome in severe steroid dependent asthmatics in whom inhaled corticosteroids allowed systemic corticosteroid withdrawal. It is concluded that physicians should monitor patients carefully when severe asthma is controlled with any substance allowing withdrawal from (or even avoidance) of systemic corticosteroids. Case-control studies should identify more precisely the risk factors of Churg-Strauss syndrome.


This article has been cited by other articles:


Home page
 ThoraxHome page
T Hauser, A Mahr, C Metzler, J Coste, R Sommerstein, W L Gross, L Guillevin, and B Hellmich
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study
Thorax, August 1, 2008; 63(8): 677 - 682.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. Boyer, S. O. Vargas, D. Slattery, Y. M. Rivera-Sanchez, and A. A. Colin
Churg-Strauss Syndrome in Children: A Clinical and Pathologic Review
Pediatrics, September 1, 2006; 118(3): e914 - e920.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M. WECHSLER, J M TUGGEY, and H S R HOSKER
Churg-Strauss syndrome with montelukast
Thorax, May 1, 2001; 56(5): 417a - 417.
[Full Text]

Home page
 NEJMHome page
P. Gruer, T. Bold, L. Vilardo, and J. P. Arm
Case 30-2000: Churg-Strauss Syndrome
N. Engl. J. Med., March 15, 2001; 344(11): 858 - 859.
[Full Text] [PDF]

Home page
 ChestHome page
S. Stoloff, D. A. Stempel, M. E. Wechsler, and J. M. Drazen
Churg-Strauss Syndrome : Is There an Association With Leukotriene Modifiers?
Chest, November 1, 2000; 118(5): 1515 - 1516.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.